Commercial Credit Report for Oryzon Genomics SA

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Oryzon Genomics SA is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Oryzon Genomics SA
Sant Ferran 74
Phone: +34 935151313p:+34 935151313	Cornella de Llobregat, BAR 08940 Spain	Ticker: ORYORY

Business Summary

Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.

(Source: 10QSB)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2023	12/31/2023	Yes	-	-	-	-

Industries

SIC Code	Description
8731	Commercial physical and biological research

Officers and Directors

Title	Name	Title Date	Start Date
Executive Chairman of the Board, Chief Executive Officer	Carlos ManuelBuesa Arjol	1/1/2015	2/20/2002
First Vice Chairwoman, Proprietary Director	TamaraMaes	1/31/2021	1/1/2000
Chief Financial Officer, Chief Operating Officer	EnricRello Condomines	5/1/2011	5/1/2011
12 additional Officers and Directors records available in full report.

General Information

Number of Employees:	44	(As of 12/31/2023)
Outstanding Shares:	62,173,519	(As of 4/12/2024)
Stock Exchange:	MCE
Fax Number:	+34 933774028

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN